Bladder Cancer VL

Unveiling the Promising Role of FAP PET Imaging in Accurate Bladder Cancer Staging - Domenique Escobar

Details
Domenique Escobar discusses her study on Fibroblast Activated Protein (FAP) PET imaging for localized bladder cancer in this conversation with Wei Shen Tan. She explains that FAP PET, a new diagnostic tool that targets proteins on cancer-associated fibroblasts, shows potential for more accurate disease staging and treatment pathways for patients. Compared to conventional imaging methods like CT, M...

Novel Models for Bladder Cancer Progression and Drug Development - John Taylor III

Details
Ashish Kamat welcomes John Taylor, III to discuss the importance of preclinical models in advancing medical innovation. He details two models based on the N-Butyl N(4-hydroxybutyl) nitrosamine (BBN) model, which is a reliable model for bladder-exclusive tumors. Taylor speaks about the benefits of the BBN model in studying muscle invasive bladder cancer, yet also underlines its shortcomings in stud...

When and How To Perform Active Surveillance for Low-risk Non–muscle-invasive Bladder Cancer - Roberto Contieri

Details
Ashish Kamat hosts Roberto Contieri, who shares his work on active surveillance as a treatment approach for low-risk non-muscle-invasive bladder cancer. Highlighting that 75% of bladder cancer patients present with non-muscle-invasive disease, he explores the merits of a conservative approach, noting its cost-effectiveness, safety, and minimal surgical risk. Contieri presents findings from the BIA...

Agent Orange and Bladder Cancer: Insights from a Study on 25 Million Veterans - Stephen Williams

Details
Stephen Williams and Sam Chang discuss the relationship between Agent Orange and bladder cancer. They highlight a retrospective cohort study conducted on over 25 million veterans to determine the association between Agent Orange exposure and bladder cancer incidence. The study controlled for various factors and found a slight increase in bladder cancer risk among veterans exposed to Agent Orange....

Exploring Tumor Biomarkers in Urothelial Carcinoma: Insights and Advancements in Bladder Cancer Research - Chad Ritch

Details
Sam Chang is joined by Chad Ritch for a discussion on tumor biomarkers and urothelial carcinoma. They discuss various types of biomarkers, including tissue-based and liquid-based markers. In the context of non-invasive bladder cancer, they mention the use of cytology as the standard despite its limitations in sensitivity. They also highlight the potential of RNA-based urinary biomarkers, such as C...

Optimizing Care of Bladder Cancer in Women - Katie Murray

Details
Katie Murray joins Ashish Kamat discusses optimizing care for bladder cancer in women. Dr. Murray highlights the need to understand the biologic and diagnostic differences, as well as the timing of diagnoses and survival disparities in bladder cancer among women. She emphasizes the importance of raising awareness among primary care physicians and advocating for early diagnosis, as women often expe...

Assessing the Effectiveness of N-803 for BCG Unresponsive Bladder Cancer: Promising Complete Remission Rates and Improved Long-Term Response - Patrick Soon-Shiong

Details
Sam Chang is joined by Patrick Soon-Shiong for a discussion on the effectiveness of N-803 for BCG unresponsive bladder cancer. They discussed the importance of an ideal profile for such an agent, which includes complete remission rate, durability of the response, and high cystectomy avoidance rate. They also highlighted the importance of the agent's safety and tolerability for urologists. The N-80...

Combining CG0070 Adenovirus Vector with Immune Checkpoint Blockade: Promising Results for BCG Unresponsive Bladder Cancer Patients - Roger Li

Details
Roger Li joins Ashish Kamat to discuss the CG0070 adenovirus vector and its potential use in combination with immune checkpoint blockade for patients with BCG unresponsive bladder cancer. The combination therapy has shown promising preliminary results, with 20 out of 22 patients achieving a complete response at three months and six out of eight patients maintaining a complete response at 12 months...

Targeting the HLA-E/NKG2A Axis to Overcome BCG Resistance in NMIBC, BCAN Translational Clinical Trial Award - Amir Horowitz

Details
Amir Horowitz joins Ashish Kamat to talk about his Bladder Cancer Translational Clinical Trial Award. An award given by the Bladder Cancer Advocacy Network (BCAN) aims to support early-phase patient-oriented research to transform bladder cancer care. The ENHANCE Trial is a phase II, single-arm trial starting with high-grade non-muscle-invasive bladder cancer (NMIBC) patients having received and fa...

The "Get Moving Trial" Home-based Pre and Rehabilitation Intervention for Muscle-invasive Bladder Cancer, BCAN Translational Clinical Trial Award - Sarah Psutka

Details
Sarah Psutka talks with Ashish Kamat about her Bladder Cancer Translational Clinical Trial Award. An award given by the Bladder Cancer Advocacy Network (BCAN) aims to support early-phase patient-oriented research to transform bladder cancer care. The "Get Moving Trial" is a phase I/II trial of a home-based pre and rehabilitation intervention for muscle-invasive bladder cancer with the use of an ap...